{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:08:37Z","timestamp":1792112917078,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ncl.2003.12.006","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:34Z","timestamp":1113821614000},"page":"389-411","source":"Crossref","is-referenced-by-count":87,"title":["The evaluation and management of patients with neuroleptic malignant syndrome"],"prefix":"10.1016","volume":"22","author":[{"given":"Minal J","family":"Bhanushali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Tuite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2003.12.006_BIB1","first-page":"145","article-title":"Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol, dans le traitmen des psychoses. (A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses) in French","volume":"18","author":"Delay","year":"1960","journal-title":"Ann Med Psychol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff","year":"1993","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ncl.2003.12.006_BIB3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0025-7125(16)30265-6","article-title":"Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant","volume":"77","author":"Heiman-Patterson","year":"1993","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ncl.2003.12.006_BIB4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1353-8020(01)00045-1","article-title":"Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide","volume":"9","author":"Reimer","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2003.12.006_BIB5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/mds.1166","article-title":"Neuroleptic malignant syndrome in advanced Parkinson's disease","volume":"6","author":"Gordon","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2003.12.006_BIB6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1345\/aph.10137","article-title":"Neuroleptic malignant syndrome during a change from haloperidol to risperidone","volume":"35","author":"Reeves","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2003.12.006_BIB7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1192\/bjp.159.6.889","article-title":"Crossover reaction between haloperidol and amoxapine for NMS","volume":"159","author":"Otani","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1034\/j.1600-0447.2000.102003226.x","article-title":"Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome","volume":"102","author":"Spivak","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ncl.2003.12.006_BIB9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0379-0738(00)00323-6","article-title":"An autopsy case of neuroleptic malignant syndrome (NMS) and its immunohistochemical findings of muscle-associated proteins and mitochondria","volume":"11","author":"Kubo","year":"2001","journal-title":"Forensic Science Int"},{"key":"10.1016\/j.ncl.2003.12.006_BIB10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bja\/85.1.129","article-title":"Neuroleptic malignant syndrome","volume":"85","author":"Adnet","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2003.12.006_BIB11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004714-199706000-00024","article-title":"Clozapine-induced neuroleptic malignant syndrome: review and report of new cases","volume":"17","author":"Sachdev","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0278-5846(02)00202-6","article-title":"Olanzapine-associated neuroleptic malignant syndrome","volume":"26","author":"Kontaxakis","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(94)90542-8","article-title":"Risperidone-induced neuroleptic malignant syndrome","volume":"344","author":"Webster","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2003.12.006_BIB14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(94)90489-8","article-title":"Risperidone-induced neuroleptic malignant syndrome in young patient","volume":"344","author":"Raitasuo","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2003.12.006_BIB15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-1614.2001.0884c.x","article-title":"Neuroleptic malignant syndrome precipitated by promethazine and lorazepam","volume":"35","author":"Duggal","year":"2001","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB16","first-page":"941","article-title":"Neuroleptic malignant syndrome due to citalopram overdose","volume":"45","author":"Aydin","year":"2000","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.155.11.1626e","article-title":"Cocaine and catatonia","volume":"155","author":"Gingrich","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1192\/bjp.159.4.572","article-title":"Neuroleptic malignant syndrome secondary to loxapine","volume":"159","author":"Chong","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1076-6332(03)80357-4","article-title":"Effects of intrathecal injection of diatrizoate on dopamine receptors","volume":"9","author":"Lasser","year":"2002","journal-title":"Acad Radiol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1053\/apmr.2002.32820","article-title":"Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome","volume":"83","author":"Coffey","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ncl.2003.12.006_BIB21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/026988110101500111","article-title":"Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen","volume":"15","author":"Turner","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.160.1.135b","article-title":"NMS complicated by diazepam","volume":"160","author":"Velamoor","year":"1992","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0006-3223(97)00530-1","article-title":"Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study","volume":"44","author":"Berardi","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome. A case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0278-5846(01)00257-3","article-title":"Toxic interaction between risperidone and clozapine: a case report","volume":"26","author":"Kontaxakis","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1592\/phco.23.6.811.32179","article-title":"Acute lithium intoxication and neuroleptic malignant syndrome","volume":"23","author":"Gill","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ncl.2003.12.006_BIB27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hup.376","article-title":"Clinical risk factors for neuroleptic malignant syndrome","volume":"17","author":"Berardi","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1192\/bjp.158.3.419","article-title":"Catatonia: harbinger of the neuroleptic malignant syndrome","volume":"158","author":"White","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0006-3223(98)00109-7","article-title":"Serum iron in catatonia and neuroleptic malignant syndrome","volume":"44","author":"Lee","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB30","first-page":"311","article-title":"Neuroleptic malignant syndrome in organic brain disease and physical illness","volume":"31","author":"Pilo","year":"1990","journal-title":"Singapore Med J"},{"key":"10.1016\/j.ncl.2003.12.006_BIB31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00004714-199808000-00022","article-title":"Acute infectious encephalitis complicated by neuroleptic malignant syndrome","volume":"18","author":"Caroff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1192\/bjp.158.6.850","article-title":"Is the predisposition to neuroleptic malignant syndrome genetically transmitted?","volume":"158","author":"Otani","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB33","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1176\/appi.ajp.158.10.1714","article-title":"Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome","volume":"158","author":"Suzuki","year":"2001","journal-title":"Am J Pychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002826-200207000-00001","article-title":"Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?","volume":"25","author":"Gurrera","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome. A case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1176\/ajp.146.6.717","article-title":"A prospective analysis of 24 episodes of neuroleptic malignant syndrome","volume":"146","author":"Rosebush","year":"1989","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-1781(96)02871-5","article-title":"Diaphoresis and dehydration during neuroleptic malignant syndrome: preliminary findings","volume":"64","author":"Gurrera","year":"1996","journal-title":"Psychiatry Res"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2003.12.006_BIB38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000113484","article-title":"NMS in Parkinson's patients:risk factors","volume":"38","author":"Kuno","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0306-3623(90)90685-F","article-title":"Pathogenesis and treatment of neuroleptic malignant syndrome","volume":"21","author":"Ebadi","year":"1990","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00004714-200206000-00004","article-title":"High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome","volume":"22","author":"Hermesh","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB41","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1176\/ajp.143.12.1587","article-title":"Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients","volume":"143","author":"Addonizio","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB42","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/0006-3223(87)90010-2","article-title":"Neuroleptic malignant syndrome: review and analysis of 115 cases","volume":"22","author":"Addonizio","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00005053-199403000-00007","article-title":"Progression of symptoms in neuroleptic malignant syndrome","volume":"182","author":"Velamoor","year":"1994","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.ncl.2003.12.006_BIB44","series-title":"Diagnostic and statistical manual of mental disorders","first-page":"739","article-title":"Neuroleptic malignant syndrome","year":"1994"},{"key":"10.1016\/j.ncl.2003.12.006_BIB45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson","year":"1985","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1345\/aph.18286","article-title":"Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature","volume":"33","author":"Karagianis","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2003.12.006_BIB47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0924-9338(00)00403-X","article-title":"Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports","volume":"15","author":"V\u00e9die","year":"2000","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0006-3223(93)90156-8","article-title":"Enzyme elevations in the neuroleptic malignant syndrome","volume":"34","author":"Gurrera","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB49","first-page":"111","article-title":"Neuroleptic malignant syndrome: a neurologic pathology of great interest for the internist","volume":"13","author":"Blasi","year":"1998","journal-title":"Ann Ital Med Int"},{"key":"10.1016\/j.ncl.2003.12.006_BIB50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0952-8180(95)00097-6","article-title":"Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal","volume":"7","author":"Young","year":"1995","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.ncl.2003.12.006_BIB51","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/bja\/85.1.118","article-title":"Malignant hyperthermia: advances in clinical management and diagnosis","volume":"85","author":"Hopkins","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2003.12.006_BIB52","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/bja\/62.5.540","article-title":"Is there a relationship between masseteric muscle spasm and malignant hyperpyrexia?","volume":"62","author":"Christian","year":"1989","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2003.12.006_BIB53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0006-3223(96)82518-2","article-title":"Neuroleptic malignant syndrome and catatonia: one entity or two?","volume":"40","author":"Northoff","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB54","first-page":"69","article-title":"[The subjective experience in catatonia: systematic study of 24 catatonic patients]","volume":"23","author":"Northoff","year":"1996","journal-title":"Psychiatr Prax"},{"key":"10.1016\/j.ncl.2003.12.006_BIB55","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.143.11.1374","article-title":"Lethal catatonia","volume":"143","author":"Mann","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB56","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0033-3182(89)72256-8","article-title":"Differentiating neuroleptic-related heatstroke from neuroleptic malignant syndrome","volume":"30","author":"Lazarus","year":"1989","journal-title":"Psychosomatics"},{"key":"10.1016\/j.ncl.2003.12.006_BIB57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0749-0704(05)70368-7","article-title":"Serotonin syndrome. A clinical update","volume":"13","author":"Mills","year":"1997","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ncl.2003.12.006_BIB58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0733-8627(05)70127-9","article-title":"The neuroleptic malignant and serotonin syndromes","volume":"18","author":"Carbone","year":"2000","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.ncl.2003.12.006_BIB59","first-page":"717","article-title":"Serotonin syndrome: case report and review of the literature","volume":"61","author":"Weiner","year":"1997","journal-title":"Conn Med"},{"key":"10.1016\/j.ncl.2003.12.006_BIB60","first-page":"588","article-title":"Data in case reports questioned","volume":"3","author":"Caroff","year":"1984","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ncl.2003.12.006_BIB61","first-page":"378","article-title":"Specific treatment of the neuroleptic malignant syndrome","volume":"44","author":"Caroff","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB62","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","article-title":"Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?","volume":"52","author":"Goetz","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2003.12.006_BIB63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1192\/bjp.164.5.689","article-title":"Recurrent sinus arrest in association with neuroleptic malignant syndrome","volume":"164","author":"Parry","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB64","first-page":"976","article-title":"Successful treatment of a complicated case of neuroleptic malignant syndrome","volume":"28","author":"Lappa","year":"2002","journal-title":"ICU Med"},{"key":"10.1016\/j.ncl.2003.12.006_BIB65","first-page":"381","article-title":"A case of neuroleptic malignant syndrome successfully treated with amantadine","volume":"43","author":"McCarron","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002826-199406000-00004","article-title":"Clinical usefulness of apomorphine in movement disorders","volume":"17","author":"Colosimo","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB67","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0006-3223(96)00519-7","article-title":"Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome","volume":"41","author":"Nisijima","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF02291355","article-title":"The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome","volume":"10","author":"Gregorakos","year":"2000","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ncl.2003.12.006_BIB69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0006-3223(97)00450-2","article-title":"Carbamazepine in the treatment of neuroleptic malignant syndrome","volume":"43","author":"Thomas","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB70","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/archinte.149.9.1927","article-title":"Neuroleptic malignant syndrome. Review of response to therapy","volume":"149","author":"Rosenberg","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ncl.2003.12.006_BIB71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1192\/bjp.159.5.709","article-title":"The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?","volume":"159","author":"Rosebush","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB72","first-page":"199","article-title":"Neuroleptic malignant syndrome. Case reports","volume":"35","author":"Berardi","year":"1994","journal-title":"Minerva Psichiatr"},{"key":"10.1016\/j.ncl.2003.12.006_BIB73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1010389215197","article-title":"Clinical management of neuroleptic malignant syndrome","volume":"72","author":"Susman","year":"2001","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.ncl.2003.12.006_BIB74","first-page":"18","article-title":"Mortality from neuroleptic malignant syndrome","volume":"50","author":"Shalev","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB75","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0447.1987.tb02782.x","article-title":"A successful electroconvulsive treatment of neuroleptic malignant syndrome","volume":"75","author":"Hermesh","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ncl.2003.12.006_BIB76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00124509-199906000-00008","article-title":"Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases","volume":"15","author":"Nisijima","year":"1999","journal-title":"J ECT"},{"key":"10.1016\/j.ncl.2003.12.006_BIB77","first-page":"267","article-title":"Treatment choice in neuroleptic malignant syndrome","volume":"8","author":"Scheftner","year":"1992","journal-title":"Convuls Ther"},{"key":"10.1016\/j.ncl.2003.12.006_BIB78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200004000-00021","article-title":"Residual catatonic state following neuroleptic malignant syndrome","volume":"20","author":"Caroff","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.ncl.2003.12.006_BIB79","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/j.1440-1614.1999.00630.x","article-title":"Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases","volume":"33","author":"Trollor","year":"1999","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.ncl.2003.12.006_BIB80","first-page":"1870","article-title":"[Malignant neuroleptic syndrome: complete anticoagulant treatment or not?]","volume":"136","author":"van Agtmael","year":"1992","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.ncl.2003.12.006_BIB81","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01705164","article-title":"A rapidly progressing lethal case of neuroleptic malignant syndrome","volume":"16","author":"Lenler-Petersen","year":"1990","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ncl.2003.12.006_BIB82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/106002808802200606","article-title":"Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review","volume":"22","author":"Wells","year":"1988","journal-title":"Drug Intell Clin Phar"},{"key":"10.1016\/j.ncl.2003.12.006_BIB83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00005053-198804000-00007","article-title":"Recurrence of neuroleptic malignant syndrome","volume":"176","author":"Susman","year":"1988","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.ncl.2003.12.006_BIB84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00004714-198710000-00010","article-title":"Reinduction of neuroleptic malignant syndrome by lithium","volume":"7","author":"Susman","year":"1987","journal-title":"J Clin Psychopharmacol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861903001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861903001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T15:49:54Z","timestamp":1550072994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861903001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0733861903001245"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2003.12.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}